Nobelpharma said on May 29 that it has obtained European regulatory approval for Hyftor (sirolimus topical gel) for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and pediatric patients aged 6 years and older. The…
To read the full story
Related Article
- Hyftor Now Available in EU, UK: Nobelpharma
October 31, 2023
- Nobelpharma Bags UK Approval for Hyftor
September 5, 2023
- Nobelpharma Makes Global Debut with US Launch of Hyftor
September 1, 2022
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





